A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC)

Autor:	Jurjees Hasan, Joanna Pikiel, Beata Mackowiak-Matejczyk, Susana Banerjee, Kedan Lin, Vanessa Lemahieu, Erika Hamilton, Yulei Wang, Jim Marsters, Michael J. Birrer, Daniel J. Maslyar, Kathleen N. Moore, Amit M. Oza, Joyce F. Liu, YounJeong Choi, Peter Trask, Isabelle Ray-Coquard, Eric W. Humke, Alexandra Leary, Anjali Vaze
Rok vydání:	2016
Předmět:	Gynecology 030213 general clinical medicine Cancer Research medicine.medical_specialty Antibody-drug conjugate business.industry medicine.drug_class food and beverages Phases of clinical research Transporter Monoclonal antibody medicine.disease Transmembrane protein 03 medical and health sciences 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Cancer research Medicine In patient business Ovarian cancer Platinum resistant
Zdroj:	Journal of Clinical Oncology. 34:5569-5569
ISSN:	1527-7755 0732-183X
Popis:	5569Background: NaPi2b is a transmembrane, sodium-dependent phosphate transporter expressed in ~90% of OC. Lifa, a humanized anti-NaPi2b monoclonal antibody conjugated to the anti-mitotic agent MMA...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::85689825b414490c360e202f29e98048 https://doi.org/10.1200/jco.2016.34.15_suppl.5569 Zobrazit plný text záznamu